Erastin and erastin binding proteins, and uses thereof

Details Erastin and erastin binding proteins, and uses thereof Erastin and erastin binding proteins, and uses thereof

2006-01-25

2009-11-10

Wilson, James O. (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S218000, C540S575000, C544S287000

Reexamination Certificate

active

07615554

ABSTRACT:
The invention relates to methods of screening for binding partners, especially binding partners essential for the biological activity of erastin (e.g. VDACs such as VDAC3). The invention also provides reagents and methods for effective killing of cancer cells with erastin and related compounds or derivatives.

REFERENCES:
patent: 6831085 (2004-12-01), Bergnes et al.
patent: 2003/0171316 (2003-09-01), Jupe
patent: 2004/0096444 (2004-05-01), Pizzo et al.
patent: 2004/0248221 (2004-12-01), Stockwell
patent: 07-258224 (1995-10-01), None
patent: 07-258224 (1995-10-01), None
patent: WO-99/21988 (1999-05-01), None
patent: WO-01/68641 (2001-09-01), None
patent: WO-02/40717 (2002-05-01), None
patent: WO-02/083143 (2002-10-01), None
patent: WO-02/099122 (2002-12-01), None
patent: WO-2004/018058 (2004-03-01), None
patent: WO-2004/030615 (2004-04-01), None
patent: WO-2004/055519 (2004-07-01), None
Machine Translation of JP 07-258224, 1995.
Ahmed, S. Ansar et al., “A new rapid and simple non-radioacive assay to monitor and determine the proliferation of lymphocytes: an alternative to [3H] thymidine incorporation assay”, Journal of Immunological Methods, 170(2): 211-224 (1994) (Abstract).
Aiken C.T., et al., “A Cell-Based Screen For Drugs to Treat Huntington's Disease”, Neurobiology of Disease, 16:546-555 (2004).
Andoh, T., et al., “Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I,” Proc Natl Acad Sci U S A, 84:5565-5569 (1987).
Bjornsti, M-A., et al., “Expression of Human DNA Topoisomerase I in Yeast Cells Lacking Yeast DAN Topoisomerase I: Restoration of Sensitivity of the Cells to the Antitumor Drug Camptotchecin,”Cancer Res, 49:6318-23 (1989).
Bosch, F.X., et al., “The causal relation between human papillomavirus and cervical cancer,” J Clin Pathol, 55:244-265 (2002).
Brown, E.J., et al., “A mammalian protein targeted by G1-arresting rapamycin-receptor complex,” Nature, 369:756-758 (1994).
Calin, G.A., et al., “Low frequency of alterations of the α (PPP2R1A) and β (PPP2R1B) isoforms of the subunit A of the serine-threonine phosphatase 2A in human neoplasms,” Oncogene, 19:1191-1195 (2000).
Capdeville, R., et al., “Glivec (STI571, IMATINIB), A Rationally Developed, Targeted Anticancer Drug,”Nat Rev Drug Discov, 1:493-502 (2002).
Champoux, J.J., “Structure-Based Analysis of the Effects of Camptothecin on the Activities of Human Topoisomerase I,” Annals New York Acad Sci, 922:56-64 (2000).
Chan, Y-M, et al., “Caspase inhibitors promote the survival of avulsed spinal motoneurons in neonatal rats,”NeuroReport, 12(3):541-5 (2001).
D'Arpa, P., et al., “Involvement of Nucleic Acid Synthesis in Cell Killing Mechanisms of Topoisomerase Poisons,”Cancer Res, 50:6919-24 (1990).
DeVita, V.T., Jr., et al., “Principles of Cancer Management: Chemotherapy,” Cancer: Principles & Practice of Oncology, Fifth Edition, 333-347 (1997).
Druker, B.J. et al., “Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells”, Nature Medicine, 2:561-566 (1996) (Abstract).
Elenbaas, B. et al., “Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells”, Genes & Development, 15:50-65 (2001).
Eng, W-K., et al., “Evidence that DNA Topoisomerase I Is Necessary for the Cytotoxic Effects of Camptothecin,”Mol Pharmacol, 34:755-60 (1988).
Hahn, W. C. and Weinberg, R. A., “Modelling the Molecular Circuitry of Cancer”, Nature Reviews Cancer, 2:331-341 (2002).
Hahn, W.C., et al., “Creation of human tumour cells with defined genetic elements,” Nature, 400:464-468 (1999).
Hahn, W.C., et al., “Enumeration of the Simian Virus 40 Early Region Elements Necessary for Human Cell Transformation,”Mol Cell Biol, 22(7):2111-23 (2002).
Hahn, W.C., et al., “Inhibition of telomerase limits the growth of human cancer cells,” Nat Med, 5(10):1164-1170 (1999).
Hamad, N. M. et al., “Distinct requirements for Ras oncogenesis in human versus mouse cells”, Genes & Development, 16:2045-2057 (2002).
Harley, C.B., “Telomerases,”Pathol Biol(Paris), 42:342-5 (1994).
Hsiang, Y-H. and Liu, L.F., “Identification of Mammalian DNA Topoisomerase I as an Intracellular Target of the Anticancer Drug Camptothecin,”Cancer Res, 48:1722-6 (1988).
Hsiang, Y-H., et al., “Arrest of Replication Forks by Drug-stabilized Topoisomerase I-DNA Cleavable Complexes as a Mechanism of Cell Killing by Camptothecin,”Cancer Res, 49:5077-82 (1989).
Jorcyk, C.L., et al., “Development and Characterization of a Mouse Prostate Adenocarcinoma Cell Line: Ductal Formation Determined by Extracellular Matrix,” The Prostate, 34:10-22 (1998).
Kohno, T., et al., “Alterations of thePPP1R3Gene in Human Cancer,”Cancer Res, 59:4170-4 (1999).
Laurent, G. and Jaffrezou, J-P., “Signaling pathways activated by daunorubicin,” Blood, 98(4):913-924 (2001).
Lessnick, S.L., et al., “The Ewing's sarcoma oncoprotein EWS/FLI induces a p53- dependent growth arrest in primary human fibroblasts,” Cancer Cell, 1:393-401 (2002).
Liu, L.F., et al., “Mechanism of Action of Camptothecin,” Annals N Y Acad Sci, 922:1-10 (2000).
Loomis, C.R. and Bell, R.M., “Sangivamycin, a Nucleoside Analogue, Is a Potent Inhibitor of Protein Kinase C*,” J Biol Chem, 263(4):1682-1692 (1998).
Madden, K.R., and Champoux, J.J., “Overexpression of Human Topoisomerase I in Baby Hamster Kidney Cells: Hypersensitivity of Clonal Isolates to Camptothecin,”Cancer Res, 52:525-32 (1992).
Majno, G. and Joris, I., “Apoptosis, Oncosis, and Necrosis,”Am J Pathol, 146(1):3-15 (1995).
Makin, G., “Targeting apoptosis in cancer chemotherapy,”Expert Opin Ther Targets, 6(1):73-84 (2002).
Miller, M.L. and Ojima, I., “Chemistry and Chemical Biology of Taxane Anticancer Agents,” Chem. Record, 1:195-211 (2001).
Millward, T.A., et al., “Regulation of protein kinase cascades by protein phosphatase 2A,” Trends Biochem Sci, 24:186-91 (1999).
Mokbel, K. and Hassanally, D., “From HER2 to Herceptin,”Curr Med Res Opin, 17(1):51-9 (2001).
Muller, I., et al., Anthracycline-derived chemotherapeutics in apoptosis and free radical cytotoxicity (Review),Int J Mol Med, 1:491-4 (1998).
Nociari, M.M., et al., “A novel one-step, highly sensitive fluorometric assay to evaluate cell-mediated cytotoxicity,”J. Immunol. Methods, 213:157-167 (1998).
Pallas, D.C., et al, “Polyoma small and middle T antigens and SV40 small t antigen form stable complexes with protein phosphatase 2A,” Cell, 60:167-176 (1990).
Perez-Stable, C., et al., “Prostate Cancer Progression, Metastasis, and Gene Expression in Transgenic Mice,”Cancer Res, 57:900-6 (1997).
Rao, K.V., “Structure of Sangivamycin,”J Med Chem, 11:939-41 (1968).
Richard, D., et al., “Free radical production and labile iron pool decrease triggered by subtoxic concentration of aclarubicin in human leukemia cell lines,” Leukemia Res, 26:927-931 (2002).
Ruediger, R., et al., “Alterations in protein phosphatase 2A subunit interaction in human carcinomas of the lung and colon with mutations in the Aβ subunit gene,” Oncogene, 20:1892-1899 (2001).
Ruediger, R., et al., “Disruption of protein phoshatase 2A subunit interaction in human cancers with mutations in the Aα subunit gene,” Oncogene, 20:10-15 (2001).
Sabatini, D.M., et al., “RAFT1: A mammalian protein that binds to KFBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs,” Cell, 78:35-43 (1994).
Sandmoller, A., et al., “A Transgenic Mouse Model for Lung Adenocarcinoma,”Cell Growth&Differ, 6:97-103 (1995).
Schreiber

Affiliated with

Also associated with

Rating

Erastin and erastin binding proteins, and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Erastin and erastin binding proteins, and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Erastin and erastin binding proteins, and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4110686